Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2003 3
2005 4
2006 3
2007 3
2008 3
2009 3
2010 1
2011 5
2012 6
2013 5
2014 1
2015 3
2016 2
2017 2
2018 5
2019 6
2020 2
2021 4
2022 2
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Results by year

Filters applied: . Clear all
Page 1
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A; ASPIRE Investigators. Stewart AK, et al. N Engl J Med. 2015 Jan 8;372(2):142-52. doi: 10.1056/NEJMoa1411321. Epub 2014 Dec 6. N Engl J Med. 2015. PMID: 25482145 Free article. Clinical Trial.
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Röllig C, Einsele H, Wu KL, Singhal A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P; ELOQUENT-2 Investigators. Lonial S, et al. Among authors: oakervee h. N Engl J Med. 2015 Aug 13;373(7):621-31. doi: 10.1056/NEJMoa1505654. Epub 2015 Jun 2. N Engl J Med. 2015. PMID: 26035255 Free article. Clinical Trial.
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.
Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV; TOURMALINE-MM3 study group. Dimopoulos MA, et al. Lancet. 2019 Jan 19;393(10168):253-264. doi: 10.1016/S0140-6736(18)33003-4. Epub 2018 Dec 10. Lancet. 2019. PMID: 30545780 Clinical Trial.
Advanced Imaging Modalities to Monitor for Cardiotoxicity.
Seraphim A, Westwood M, Bhuva AN, Crake T, Moon JC, Menezes LJ, Lloyd G, Ghosh AK, Slater S, Oakervee H, Manisty CH. Seraphim A, et al. Among authors: oakervee h. Curr Treat Options Oncol. 2019 Aug 8;20(9):73. doi: 10.1007/s11864-019-0672-z. Curr Treat Options Oncol. 2019. PMID: 31396720 Free PMC article. Review.
Optimising cardiovascular care of patients with multiple myeloma.
Fontes Oliveira M, Naaktgeboren WR, Hua A, Ghosh AK, Oakervee H, Hallam S, Manisty C. Fontes Oliveira M, et al. Among authors: oakervee h. Heart. 2021 Nov;107(22):1774-1782. doi: 10.1136/heartjnl-2020-318748. Epub 2021 Apr 5. Heart. 2021. PMID: 33820757 Review.
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
Dimopoulos MA, Richardson PG, Bahlis NJ, Grosicki S, Cavo M, Beksaç M, Legieć W, Liberati AM, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach JP, Petrucci MT, Reece D, White D, Mateos MV, Špička I, Lazaroiu M, Berdeja J, Kaufman JL, Jou YM, Ganetsky A, Popa McKiver M, Lonial S, Weisel K; ELOQUENT-1 investigators. Dimopoulos MA, et al. Lancet Haematol. 2022 Jun;9(6):e403-e414. doi: 10.1016/S2352-3026(22)00103-X. Epub 2022 May 9. Lancet Haematol. 2022. PMID: 35550060 Free article. Clinical Trial.
Cessation of Ciprofloxacin Prophylaxis in Hemato-Oncology Patients.
Caldwell L, Bapat A, Drumright LN, Lambourne J, Jimenez-England FG, Aries J, Eccersley L, Hallam S, Montoto S, Oakervee H, Riches J, Agrawal SG. Caldwell L, et al. Among authors: oakervee h. Clin Infect Dis. 2022 Aug 24;75(1):178-179. doi: 10.1093/cid/ciab1000. Clin Infect Dis. 2022. PMID: 34864924 Free PMC article. No abstract available.
Bortezomib for multiple myeloma.
Popat R, Joel S, Oakervee H, Cavenagh J. Popat R, et al. Among authors: oakervee h. Expert Opin Pharmacother. 2006 Jul;7(10):1337-46. doi: 10.1517/14656566.7.10.1337. Expert Opin Pharmacother. 2006. PMID: 16805719 Review.
Clinical outcome of coronavirus disease 2019 in haemato-oncology patients.
Aries JA, Davies JK, Auer RL, Hallam SL, Montoto S, Smith M, Sevillano B, Foggo V, Wrench B, Zegocki K, Agrawal S, Le Dieu R, Truelove E, Erblich T, Araf S, Okosun J, Oakervee H, Cavenagh JD, Gribben JG, Riches JC. Aries JA, et al. Among authors: oakervee h. Br J Haematol. 2020 Jul;190(2):e64-e67. doi: 10.1111/bjh.16852. Epub 2020 Jun 10. Br J Haematol. 2020. PMID: 32420609 Free PMC article. No abstract available.
54 results